Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Scott S. Tykodi"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Tumor-associated endothelial cells (TECs) are crucial mediators of immune surveillance and immune escape in the tumor microenvironment (TME). TECs driven by angiogenic growth factors form an abnormal vasculature which deploys molecular machinery to s
Externí odkaz:
https://doaj.org/article/260e213f809045e5ad192a635db49c20
Autor:
Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodi
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 46, Iss , Pp 100948- (2023)
Metastatic renal cell carcinoma (RCC) remains an incurable disease for most patients highlighting an urgent need for new treatments. However, the preclinical investigation of new therapies is limited by traditional two-dimensional (2D) cultures which
Externí odkaz:
https://doaj.org/article/9a6a0ba591d64c2b98c9db933ac8344f
Autor:
Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Publikováno v:
Cancer Medicine, Vol 11, Iss 16, Pp 3106-3114 (2022)
Abstract Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setti
Externí odkaz:
https://doaj.org/article/5a0bc07a3300429c841ed05a5967d215
Autor:
Scott S. Tykodi, Renate Pichler
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/2178d36828204ecfae6423980d98e10a
Autor:
Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Chris P. Miller, Scott S. Tykodi, Edus H. Warren
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Objective responses of metastatic renal cell carcinoma (RCC) associated with systemic immunotherapies suggest the potential for T-cell-mediated tumor clearance. Recent analyses associate clonally expanded T cells present in the tumor at diagnosis wit
Externí odkaz:
https://doaj.org/article/0138d642c53e44d4b870bb69d299c4c9
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 1882-1896 (2021)
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selective
Externí odkaz:
https://doaj.org/article/fdeb72bf1a044f61940f92e772545845
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Toni K Choueiri, David F McDermott, Jaime Merchan, Todd M Bauer, Robert Figlin, Elisabeth I Heath, M Dror Michaelson, Edward Arrowsmith, Anishka D'Souza, Song Zhao, Ananya Roy, Rodolfo Perini, Donna Vickery, Scott S Tykodi
Publikováno v:
The Lancet Oncology. 24:553-562
Autor:
Christopher P. Miller, Farinaz Shokri, Shreeram Akilesh, Yuexin Xu, Edus H. Warren, Scott S. Tykodi, Maria Tretiakova
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 31:135-144
Autor:
Daniel C. Cho, Michael E. Hurwitz, Chantale Bernatchez, Yijie Liao, Ernesto Iacucci, Ahsan Rizwan, Christie Fanton, Sandra Aung, Ute Hoch, Alison L. Hannah, Jonathan Zalevsky, Mary A. Tagliaferri, Brendan D. Curti, Scott S. Tykodi, Mario Sznol, Scott N. Gettinger, Harriet M. Kluger, Cara Haymaker, Vassiliki Papadimitrakopoulou, Patrick Hwu, Salah-Eddine Bentebibel, Nizar M. Tannir, Adi Diab
This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76d9b8ad447190ee9c1740fd458386d6
https://doi.org/10.1158/2159-8290.c.6547937.v1
https://doi.org/10.1158/2159-8290.c.6547937.v1